The Supreme People's Court of China ruled favorably on the patent of the compound peptide of Somamerica.

On December 31, 2025, the Supreme People's Court of China made a favorable ruling on the patent-related intellectual property of the semaglutide compound. Novo Nordisk A/S Sponsored ADR Class B (NVO.US) is delighted that the Supreme People's Court supported the Beijing Intellectual Property Court's decision to maintain the validity of the semaglutide compound patent. Mads Thomsen, Global President and CEO of Novo Nordisk A/S Sponsored ADR Class B, said, "This decision is of great significance for semaglutide, and it fully demonstrates the firm support of the Chinese government in protecting medical innovation. This decision not only strengthens the confidence of foreign enterprises in sustainable development in China but also further promotes the research and development of innovative drugs, benefiting patients." Semaglutide is a novel long-acting glucagon-like peptide-1 (GLP-1) analog developed by Novo Nordisk A/S Sponsored ADR Class B, which is the main component of the anti-obesity drug Wegovy (domestic trade name: Novoheid) and the adult type 2 diabetes drug Ozempic (domestic trade name: Novotai) and Rybelsus (domestic trade name: Novoxin). Since its launch, semaglutide has been widely recognized clinically and has accumulated experience in use by approximately 38 million patient-years. Previously, Novo Nordisk A/S Sponsored ADR Class B stated that the semaglutide compound patent is set to expire in certain markets within the international operations department, and it is expected to have a low single-digit negative impact on the company's global sales growth in 2026. This ruling does not change this expectation.